Smart Insulin Patch Delivery Systems for Glucose-Responsive Glycemic Control in Diabetic Patients

Kibibi Wairimu H.

School of Natural and Applied Sciences Kampala International University Uganda

                                                                                    ABSTRACT
Diabetes mellitus affects over 537 million adults globally, with inadequate glycemic control contributing to severe microvascular and macrovascular complications. Conventional insulin therapy, including multiple daily injections and continuous subcutaneous insulin infusion, failed to mimic physiological insulin secretion patterns, resulting in hypoglycemic episodes and suboptimal glucose homeostasis. Smart insulin patch delivery systems represented an emerging biomedical engineering approach that integrates glucose-sensing mechanisms with controlled insulin release, offering automated, physiologically responsive treatment modalities. This review critically evaluated the biochemical foundations, technological architectures, clinical efficacy, and translational potential of glucoseresponsive smart insulin patches for diabetes management. A comprehensive literature search of peer-reviewed articles published between 2014 and 2024 was conducted across PubMed, Web of Science, and Scopus databases using terms related to glucose-responsive insulin delivery, microneedle patches, and closed-loop systems. Current smart patch platforms employ diverse glucose-sensing mechanisms including phenylboronic acid derivatives, glucose oxidase enzymatic systems, and concanavalin A lectin-based recognition. Microneedle arrays facilitate minimally invasive transdermal delivery while maintaining mechanical integrity and biocompatibility. Preclinical studies demonstrated rapid glucose-responsive insulin release within 30 to 60 minutes, sustained euglycemia for 10 to 20 hours, and reduced hypoglycemic events compared to conventional therapy. However, human clinical trials remain limited, with challenges including long-term biocompatibility, sensor drift, and regulatory pathway complexity. Glucose-responsive insulin patches demonstrated substantial preclinical promise for physiological glycemic control, yet require rigorous clinical validation, standardized performance metrics, and manufacturing scalability before clinical implementation.

Keywords: Glucose-responsive insulin delivery, Smart insulin patch, Microneedle technology, Closed-loop diabetes management, Phenylboronic acid.

CITE AS: Kibibi Wairimu H. (2026). Smart Insulin Patch Delivery Systems for Glucose-Responsive Glycemic Control in Diabetic Patients. Research Output Journal of Engineering and Scientific Research
5(1): 36-42. https://doi.org/10.59298/ROJESR/2026/5.13642